The Clearance-Rebalancing Research Program

A Governed, Citizen-Funded Roadmap for Rebuilding Alzheimer’s Science

Status: Public-Safe White Paper

Version: 1.0

Classification: Research Infrastructure & Governance Plan

License: Open Science Non-Aggression License (OSNA)

Affiliation: CollectiveOS / Human Global Science Collective

Abstract

Alzheimer’s disease research has spent decades prioritizing molecular removal strategies, particularly amyloid plaque clearance, with limited functional success and significant safety tradeoffs. This has produced a widening gap between biological insight and patient outcomes, eroding public trust and exhausting traditional funding models. This white paper introduces the Clearance-Rebalancing Research Program (CRP): a staged, governed, citizen-funded research initiative designed to rebuild Alzheimer’s science from the ground up. Rather than proposing a treatment or intervention, the CRP funds evidence generation, systems analysis, and safety-first research infrastructure, explicitly separating research preparation from clinical action. The program is designed to be publicly transparent, ethically bounded, regulator-aware, and compatible with open science principles. It establishes a reproducible pathway from hypothesis to evidence without exposing participants to medical risk or promoting unverified therapies.

1. Introduction: The Structural Necessity of a New Research Architecture

1.1 The Epistemological Crisis in Neurodegeneration

The field of neurodegenerative research faces a crisis that is not merely biological but structural. For over three decades, the scientific consensus has coalesced around the "Amyloid Cascade Hypothesis," a linear, mechanism-first model positing that the accumulation of amyloid-beta (Aβ) plaques is the primary causative agent of neuronal death.1 This reductionist ontology dictated a clear mandate: identify the mechanism of accumulation and engineer a counter-mechanism to obliterate it. The resulting therapeutic landscape, dominated by high-affinity monoclonal antibodies (mAbs), has largely succeeded in its mechanistic goal of plaque reduction but has frequently failed to translate these molecular victories into meaningful patient outcomes.

This disconnect represents a failure of "Mechanism-First Medicine." By prioritizing the removal of a symptom (plaque) without respecting the broader system constraints (vascular integrity, metabolic reserve, and fluid dynamics), traditional interventions have precipitated "iatrogenic disintegration" of the neurovascular unit (NVU).1 The prevalence of Amyloid-Related Imaging Abnormalities (ARIA), manifesting as cerebral edema and microhemorrhages, serves as a stark indicator that the therapeutic "load" often exceeds the biological "bearing capacity" of the aging brain.

The Clearance-Rebalancing Research Program (CRP) is founded on the premise that solving this crisis requires more than a new drug target; it requires a new research operating system. We must shift from an extractive, industrial model of drug development—where biological targets are "mined" and "attacked"—to a constraint-based, homeostatic model of systems engineering. This white paper outlines the governance, infrastructure, and execution roadmap for such a shift.

1.2 The Failure of Traditional Funding and Trust

The financial and ethical structures supporting Alzheimer's research have become as fragile as the neurovascular systems they seek to treat. The "Valley of Death" in pharmaceutical development—the gap between basic research and clinical validation—has widened, driven by the astronomical costs of late-stage clinical trials and the high failure rate of amyloid-targeting agents. This economic pressure creates a perverse incentive structure: research programs become "too big to fail," leading to data dredging, post-hoc analysis, and the over-promotion of marginal statistical benefits as clinical breakthroughs.

Simultaneously, the rise of the unregulated "longevity" market has eroded public trust. Desperate patients, alienated by the slow pace of institutional science, are increasingly victimized by "biohacking" clinics offering unverified "blood washing" or "young blood" infusions.1 These interventions, often operating in a regulatory gray zone, lack the safety protocols, ethical oversight, and data rigor required to generate valid scientific knowledge.

The CRP addresses this dual failure by establishing a "Citizen-Funded, Governed" model. By decoupling funding from the profit motives of pharmaceutical monopolies and the risk-aversion of federal grants, we empower a distributed network of stakeholders—patients, clinicians, and citizen scientists—to fund and oversee research that prioritizes safety and transparency. However, this democratization requires rigorous governance. The CRP introduces "GATA PRIME," an algorithmic safety protocol that replaces the opaque, retrospective oversight of traditional Institutional Review Boards (IRBs) with transparent, real-time, logic-based compliance.

1.3 The Constraint-First Ontology: A New Operating System

The intellectual core of the CRP is the "Constraint-First" ontology. In standard biomedical research, the focus is on the mechanism (how a molecule moves or binds). In the CRP framework, the focus is on the constraint (the boundary conditions that allow the system to exist). As detailed in the "Nunatak Cryo-Vault Hypothesis" and the CollectiveOS architecture, preservation in complex systems is the result of "Stability Kernels" that manipulate stress fields to minimize entropy.1

Applied to Alzheimer’s research, this means we do not ask, "How much amyloid can we remove?" We ask, "How much clearance can the patient's vascular system withstand?".1 This shift from aggressive intervention to homeostatic rebalancing defines every aspect of the CRP, from its clinical protocols to its data governance. We view the plaque not merely as a pathogen but as a "load-bearing" symptom—a biological sealant recruited by a failing system. Removing it requires a "Clearance-Rebalancing" approach: a coordinated effort to restore the system's capacity to clear waste (Clearance) while simultaneously supporting the metabolic and vascular structures that maintain coherence (Rebalancing).

2. Program Architecture: The Clearance-Rebalancing Framework

2.1 The Pilot Candidate: Cognitive Plaque Remediation

While the CRP is a governance infrastructure capable of supporting multiple research lines, its inaugural pilot program is "Cognitive Plaque Remediation." This specific research candidate was selected because it perfectly illustrates the need for a constraint-based, systems-biology approach. It serves as the "Keystone" project to validate the CRP's governance and funding models.

The Cognitive Plaque Remediation framework posits that neurodegeneration is a "flow stagnation" problem rather than a production problem.1 In sporadic AD, the brain's ability to clear metabolic waste via the glymphatic system and the blood-brain barrier (BBB) fails. The CRP proposes to investigate a therapeutic architecture that restores this flow through two coupled mechanisms:

1. Systemic Clearance (The Pull): utilizing Therapeutic Plasma Exchange (TPE) with albumin replacement to restore the "Peripheral Sink" gradient, drawing amyloid out of the brain without invasive interaction.1

2. Central Optimization (The Push): utilizing non-invasive glymphatic support (sleep architecture optimization, pulsatility support) to mobilize waste from the parenchyma to the perivascular spaces.1

This candidate is not a "cure" but a "remediation framework"—a systems-engineering approach to managing a chronic waste management failure.

2.2 The "Safe Operating Area" (SOA) Definition

A central tenet of the CRP is the definition of the "Safe Operating Area" (SOA) for clinical research. Traditional trials often push dosing to the "Maximum Tolerated Dose" (MTD), accepting significant toxicity in pursuit of efficacy. The CRP rejects the MTD paradigm in favor of the "Optimal Homeostatic Range."

Table 1: Defining the Safe Operating Area (SOA) for CRP Protocols

 

The SOA is not a static guideline but a computable boundary condition. Using Constraint-Based Reconstruction and Analysis (COBRA) and Genome-Scale Metabolic Models (GEMs) 1, the CRP aims to model the patient's metabolic capacity to withstand the energy demands of waste clearance. If the "cost" of clearing amyloid exceeds the patient's ATP generation capacity, the intervention is algorithmically throttled. This prevents the "metabolic excitotoxicity" that often causes late-stage trial failures.

2.3 The Separation of Concerns: Architecture vs. Fabrication

The CRP adheres to the Huntsville Protocol for patent-free, verification-first innovation.1 This requires a strict separation between the "Architectural Disclosure" (the public-safe white paper and protocols) and the "Fabrication Details" (specific device settings, proprietary algorithms, and patient-specific data).

• Public Layer (Zenodo-Ready): The CRP publishes the full system architecture, the biological hypothesis, the governance logic, and the aggregate outcomes. This allows for global peer review and replication of the concept.

• Protected Layer (Proof-Vault): The granular execution data—individual patient biometrics, the real-time decision logs of the safety AI, and the specific manufacturing controls for therapeutic albumin—are secured in WORM (Write Once, Read Many) certified vaults. This prevents the dual-use proliferation of dangerous "blood washing" techniques while maintaining a verifiable audit trail for regulators.1

3. Governance Infrastructure: GATA PRIME and Algorithmic Safety

3.1 The Necessity of Algorithmic Governance

In the high-stakes environment of neurodegenerative research, human oversight is insufficient. Institutional Review Boards (IRBs) meet intermittently and review safety data retrospectively. A patient may suffer an adverse event weeks before the IRB is notified. The CRP replaces this latency with GATA PRIME (Governance, Audit, Trust, Authority - Temporal Logic Safety), an automated governance layer that enforces safety constraints in real-time.1

GATA PRIME is not "AI" in the sense of a generative chatbot or a black-box neural network. It is a deterministic "Logic Gate" system based on Linear Temporal Logic (LTL). It encodes the "Do No Harm" principle into executable code that governs the research infrastructure.

3.2 The Governance Stack

The governance model operates in a three-tier vertical stack, ensuring that every action is validated before execution.

3.2.1 Tier 1: Quality Control (QC) - The Physical Layer

Before any participant interacts with the protocol, the physical inputs must be validated.

• Chain of Custody: The therapeutic albumin used in TPE must be verified for origin, sterility, and specific biochemical properties (e.g., free thiol content at Cys34).1

• Hardware Calibration: The apheresis devices must pass automated self-checks for flow rate accuracy and pressure sensor latency.

• Logic: IF Albumin_Source!= Certified THEN Lock_Procedure

3.2.2 Tier 2: GATA (Governance, Audit, Trust, Authority) - The Eligibility Layer

This layer manages the static constraints of the participant and the regulatory environment.

• Exclusion Criteria Enforcement: The system automatically checks patient electronic health records (EHR) against the "Constraint Model." Is the vascular system stable? Is renal function adequate ($C_R$)? Is the patient on anticoagulants?.1

• Regulatory Reporting: Ensures that the procedure is registered in the CMS-mandated registry and that FDA IDE reporting requirements are met before the procedure begins.

• Logic: IF Patient_GFR < 60 OR Anticoagulant_Status == True THEN Deny_Eligibility

3.2.3 Tier 3: GATA PRIME - The Temporal Safety Layer

This is the "God File"—the immutable safety logic that governs the active research session.1 GATA PRIME monitors real-time biomarkers and biometric feeds (HRV, blood pressure, potentially inline fluid analytics). It enforces temporal safety rules using LTL syntax.

Example GATA PRIME Logic Constraints:

1. The Vascular Integrity Rule:
   AG (Action == "TPE_Flow_High" -> Vascular_Shear_Stress < Max_Limit)
   Interpretation: Always Globally, if the flow rate is high, the calculated shear stress must remain below the patient-specific maximum.

2. The Neuronal Safety Brake:
   AG (Biomarker_NfL > Baseline + 10% -> STOP_Therapy)
   Interpretation: If Neurofilament Light Chain (a marker of axonal injury) rises by more than 10% above baseline, immediately halt the intervention.1

3. The Metabolic Governor:
   AG (Metabolic_Reserve < Critical_Threshold -> Throttle_Clearance_Rate)
   Interpretation: If the patient's estimated ATP reserve drops (indicating metabolic exhaustion), reduce the intensity of the clearance to prevent excitotoxicity.

3.3 The "God File" Concept

The set of GATA PRIME rules constitutes the "God File." In the CRP architecture, this file is cryptographically signed and version-controlled. Once a research protocol is active, no human operator—not the principal investigator, not the clinician, not the patient—can override a GATA PRIME safety halt. This "Safety as Code" approach protects participants from the optimism bias of researchers and the desperation of patients. It ensures that the research remains an inquiry into safety and efficacy, not a reckless pursuit of results.

4. Operational Roadmap: Staged Execution

The CRP is not a single clinical trial but a multi-stage program designed to build evidence from the bottom up. We reject the "Moonshot" approach of jumping straight to Phase 3 trials. Instead, we follow a rigorous "Crawl, Walk, Run" trajectory.

Phase 0: In Silico Validation & Constraint Modeling (Current Status)

• Objective: Define the theoretical boundaries of the Safe Operating Area.

• Activities:

• Metabolic Modeling: Utilize the iHuman Brain2690 genome-scale metabolic model to simulate the ATP costs of repolarizing AQP4 channels and transporting albumin-Aβ complexes.1

• Fluid Dynamics Simulation: Model the shear stress on CAA-laden vessels under various TPE flow rates to establish $C_V$ (Vascular Constraint) limits.

• GATA Logic Definition: Code the initial LTL rulesets for the GATA PRIME safety kernel.

• Deliverable: The "Cognitive Plaque Remediation" White Paper (Version 1.0) and the GATA PRIME Technical Specification.

Phase 1: The Observational Biomarker Study (Evidence Generation)

• Objective: Validate the "Peripheral Sink" gradient and baseline biomarker volatility in the target population without intervention.

• Methodology: A non-interventional, longitudinal study of patients with mild-to-moderate AD.

• Key Metrics:

• Correlation between plasma Aβ42/40 ratio and CSF/PET amyloid burden.1

• Baseline variability of p-tau217 and NfL over time.

• Evaluation of "Albumin Capacity" (oxidative status of patient albumin) to confirm the "dirty sponge" hypothesis.1

• Funding Model: Citizen-funded "Biomarker Grants." Donors fund specific biomarker panels, receiving tokenized (anonymized) confirmation that the data was generated and uploaded to the Proof-Vault.

Phase 2: The IDE Pilot (Interventional Safety)

• Objective: Assess the safety and feasibility of the Clearance-Rebalancing protocol under GATA PRIME governance.

• Regulatory Status: Conducted under an FDA Investigational Device Exemption (IDE).1

• Cohort: Small, highly stratified group (n=10-20) with confirmed amyloid pathology but stable vascular status.

• Intervention:

• Systemic: Low-volume Therapeutic Plasma Exchange with 5% Albutein replacement.

• Central: Coupled with sleep optimization protocols.

• Governance: Fully active GATA PRIME monitoring.

• Constraint: The study is powered for safety (NfL stability, no ARIA), not cognitive improvement. This manages expectations and prevents hype.

Phase 3: The Adaptive Efficacy Trial (CMS Alignment)

• Objective: Demonstrate functional stabilization (ADAS-Cog, iADRS) to support reimbursement.

• Design: An adaptive platform trial where the "Rebalancing" parameters (metabolic support, glymphatic drivers) can be tuned based on intermediate Bayesian analysis.

• Alignment: Designed to meet CMS "Coverage with Evidence Development" (CED) criteria 1, ensuring that if successful, the therapy is immediately reimbursable for Medicare beneficiaries.

5. The Science of the Candidate: Cognitive Plaque Remediation

While the CRP is the governance container, it is essential to detail the scientific hypothesis it is currently built to test. The "Cognitive Plaque Remediation" framework is distinct from standard anti-amyloid therapies in its mechanism, targets, and safety profile.

5.1 The Peripheral Sink Hypothesis: Thermodynamics over Pharmaceutics

Standard mAbs (Lecanemab, Donanemab) operate on a Pharmacologic principle: they introduce a foreign agent (antibody) to bind a target. The CRP operates on a Thermodynamic principle: it alters the concentration gradient to induce diffusion.

• The Gradient: Aβ exists in equilibrium between the brain (ISF) and blood (Plasma). In AD, this equilibrium is stalled because the plasma albumin (the "sink") is saturated and oxidized.1

• The Intervention: By removing the saturated plasma and replacing it with fresh, high-affinity albumin, we lower the chemical potential of Aβ in the periphery.

• The Result: Aβ diffuses down the gradient, crossing the BBB via LRP1 transporters. This "pull" is uniform across the vascular tree, avoiding the focal "hotspots" of inflammation caused by antibody binding.1

5.2 The Glymphatic Coupling: Flushing the System

The "Pull" of TPE is insufficient if the "Push" of the glymphatic system is broken. The CRP recognizes the "Glymphatic-Lymphatic Continuum" 1 as the critical path for central clearance.

• Viscosity & Pulsatility: TPE removes fibrinogen and lipids, significantly lowering plasma viscosity.1 This rheological change improves microvascular perfusion and increases the arterial pulsatility that drives the glymphatic pump.

• Sleep Architecture: Since glymphatic clearance is upregulated during Slow Wave Sleep (SWS), the CRP protocol couples TPE sessions with sleep monitoring. We aim to "empty the sink" (blood) exactly when the "faucet" (brain flush) is open.

5.3 Vascular Preservation: The "Constraint"

The primary failure mode of anti-amyloid therapy is ARIA—vascular damage. The CRP prevents this by adhering to the "Vascular Shear Strength" constraint ($C_V$).

• Mechanism of Safety: Unlike mAbs, which trigger complement activation and microglial attack on the vessel wall, albumin is a natural stabilizer. It provides oncotic pressure (preventing edema/ARIA-E) and acts as a radical scavenger (preventing oxidative damage).1

• Differentiation: We are reinforcing the vessel wall while cleaning it. This is the definition of "Rebalancing."

6. Data Infrastructure and Open Science Alignment

6.1 The Proof-Vault: WORM Certified Provenance

To rebuild trust, data must be immutable. The CRP utilizes a "Proof-Vault" architecture for data storage. All raw data—biomarker levels, GATA PRIME decision logs, and adverse event reports—are hashed and anchored to a Write Once, Read Many (WORM) storage layer.1 This ensures that negative results cannot be buried and positive results cannot be manipulated.

6.2 Dual Proof Architecture

The CRP solves the tension between Open Science and Patient Privacy using a Dual Proof Architecture:

1. Logical Proof (Public): We openly publish the logic of the GATA PRIME algorithms, the statistical outcomes of the trials, and the systems biology models. This allows the scientific community to verify the "Why" and "How".1

2. Physical Proof (Private): The actual patient records and the specific "fabrication" details of the GATA PRIME runtime are kept private, verified via Zero-Knowledge Proofs (ZKPs). A ZKP can prove to a regulator or auditor that "All patients met safety criteria" without revealing the identity or specific medical history of any single patient.1

6.3 The Open Science Non-Aggression License (OSNA)

The CRP operates under the OSNA. This license permits the free use of the "Cognitive Plaque Remediation" architectural patterns for research and non-commercial verification. However, it includes "Constraint Clauses" that revoke the license if the technology is used for:

• Unregulated "biohacking" or commercial longevity clinics without GATA oversight.

• Procedures that violate the defined Safety Operating Area (e.g., "young blood" infusions).

7. Regulatory and Ethical Alignment

7.1 Distinguishing Medicine from Biohacking

The CRP draws a hard line between its protocols and the "gray market" of blood washing.

• No "Young Blood": We strictly disavow parabiosis. The CRP uses pharmaceutical-grade Albutein (human albumin), a sterile, FDA-approved product. We do not use donor plasma from young individuals, citing FDA warnings regarding anaphylaxis and infection risks.1

• No "Optimization" Claims: We do not promise "rejuvenation." We research "remediation" of a specific pathological protein load.

• Institutional Oversight: All CRP research is conducted under the oversight of registered IRBs and within the framework of FDA IDE applications.1

7.2 FDA and CMS Pathways

• Investigational Device Exemption (IDE): The CRP frames the TPE/Albumin/Software system as a "Combination Product" or a "Device" (due to the apheresis hardware and SaMD component). We pursue the IDE pathway 1 to legitimize the safety data.

• CMS Coverage: By aligning with the "Coverage with Evidence Development" (CED) program 1, the CRP ensures that the evidence generated is specifically formatted to answer the questions Medicare needs answered: "Is this reasonable and necessary? Does it improve health outcomes?"

7.3 Risk Management Standards

The CRP adopts ISO 14971 (Application of risk management to medical devices) and IEC 62366 (Application of usability engineering) as its foundational operational standards.1 Every aspect of the GATA PRIME code is mapped to a Hazard Analysis, ensuring that the system is "Inherently Safe by Design."

8. Funding and Sustainability: The Citizen-Science Model

8.1 The Economic Collapse of Monopoly Medicine

Current Alzheimer's treatments are economically toxic. Monoclonal antibodies cost ~$26,000/year, require expensive PET scans for monitoring, and demand specialized infusion centers.1 This creates a "scarcity model" where only the wealthy or well-insured can access care.

The CRP disrupts this model through "Architectural Anti-Scarcity".1

• Commodity Inputs: Albumin is a generic biologic produced globally. Apheresis machines are standard equipment in almost every hospital.

• Distributed Governance: GATA PRIME is software. It scales infinitely at near-zero marginal cost.

• Result: By shifting value from the molecule (proprietary IP) to the protocol (Open Science), we dramatically lower the cost of delivery.

8.2 The Citizen-Funded Mechanism

The CRP utilizes a crowdfunding model that treats donors as "Research Patrons" rather than investors.

• Micro-Grants: Funds are raised for specific "Data Blocks" (e.g., "Fund the p-tau217 analysis for 10 patients").

• Transparency: Donors receive updates via the Proof-Vault, verifying exactly where their funds went (e.g., "Batch #402 of Albumin purchased").

• No Equity/No Token: To remain compliant with securities law and ethical norms, the CRP does not offer equity or speculative tokens. The return on investment is knowledge—the acceleration of a public-safe cure.

9. Second-Order Implications: A Template for Systems Medicine

The Clearance-Rebalancing Research Program is more than a plan for Alzheimer's; it is a template for the future of Systems Medicine.1 It demonstrates how we can move from:

• Mechanism-First $\rightarrow$ Constraint-First

• Proprietary/Closed $\rightarrow$ governed/Open

• Extractive/Attack $\rightarrow$ Homeostatic/Rebalancing

By respecting the complex interplay of physics, biology, and economics, the CRP offers a roadmap out of the "Valley of Death." It proposes that the cure for neurodegeneration is not a magic bullet, but a governed, re-engineered flow. We are not just washing blood; we are building the infrastructure of preservation.

10. Conclusion

The "gap" in Alzheimer's research—between the billions spent and the lives lost—is not a failure of effort, but a failure of architecture. We have been trying to force a linear solution onto a non-linear system. The Clearance-Rebalancing Research Program offers a correction. It provides the governance to ensure safety, the roadmap to ensure validity, and the funding model to ensure accessibility.

This white paper is the "Keystone Document" [User Query]. It ties the biological hypothesis to the operational reality. It serves as the justification for the crowdfunding campaign, the roadmap for the clinicians, and the pledge of safety to the patients. It is time to rebuild Alzheimer's science, not from the molecule up, but from the constraint down.

Appendix A: Detailed Biomarker Stratification Table

Table 2: Biomarker Stratification for Cognitive Plaque Remediation

 

Appendix B: Technical Explainer - Why "Young Blood" is a Myth

For the Skeptic and the Clinician:

The media often conflates Therapeutic Plasma Exchange (TPE) with "Parabiosis" or "Young Blood Transfusions." It is critical to distinguish the CRP from these unscientific practices.

The "Young Blood" Myth:

• Concept: Infusing plasma from young donors (ages 16-25) into older adults to transfer undefined "youth factors."

• Science: Unproven. The FDA warns of risks including anaphylaxis, transfusion-associated lung injury (TRALI), and infection.1

• Regulation: Unregulated, off-label, often performed in "Biohacking" clinics.

• CRP Stance: PROHIBITED.

The CRP Reality (TPE + Albumin):

• Concept: Removing waste-laden plasma and replacing it with pure, therapeutic-grade Albumin.

• Science: Validated by the AMBAR trial (NCT01561053).1 The mechanism is removal (clearance) via concentration gradients, not addition of magic factors.

• Material: Uses Albutein® (or generic equivalent)—a sterile, heat-treated, fractionated pharmaceutical product.

• Regulation: FDA-cleared hardware; IDE-governed protocol; CMS-aligned data generation.

The CRP is a waste management program, not a fountain of youth.

Appendix C: GATA PRIME Logic Flowchart (Text Description)

1. START Session

2. CHECK Hardware_ID && Albumin_Lot_ID (Must match QC Database).

• Fail: LOCK System.

1. CHECK Patient_Biometrics (HRV, BP, SpO2).

• Constraint: Is Patient in "Parasympathetic/Rest/Digest" state?

• Fail: PAUSE. Instruct "Calibrate/Relax."

1. INITIATE Flow_Ramp_Up.

• Constraint: Rate of change $\le$ Vascular Constraint Limit ($C_V$).

1. MONITOR LOOP (100ms interval):

• Shear_Stress_Calc based on Flow/Viscosity.

• Metabolic_Reserve_Est based on Glucose/O2 extraction.

• Adverse_Event_Signal (Nurse input or Bio-alarm).

• IF Any Constraint Violated $\rightarrow$ THROTTLE or STOP.

1. END Session $\rightarrow$ LOG to Proof-Vault.

Works cited

1. White Paper Outline_ Cognitive Plaque Remediation.pdf